172 related articles for article (PubMed ID: 35867755)
1. EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1α pathway.
Qiu Z; Guo W; Dong B; Wang Y; Deng P; Wang C; Liu J; Zhang Q; Grosschedl R; Yu Z; Deng J; Wu Y
Proc Natl Acad Sci U S A; 2022 Jul; 119(28):e2119518119. PubMed ID: 35867755
[TBL] [Abstract][Full Text] [Related]
2. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway.
Chen X; Iliopoulos D; Zhang Q; Tang Q; Greenblatt MB; Hatziapostolou M; Lim E; Tam WL; Ni M; Chen Y; Mai J; Shen H; Hu DZ; Adoro S; Hu B; Song M; Tan C; Landis MD; Ferrari M; Shin SJ; Brown M; Chang JC; Liu XS; Glimcher LH
Nature; 2014 Apr; 508(7494):103-107. PubMed ID: 24670641
[TBL] [Abstract][Full Text] [Related]
3. ZHX2 promotes HIF1α oncogenic signaling in triple-negative breast cancer.
Fang W; Liao C; Shi R; Simon JM; Ptacek TS; Zurlo G; Ye Y; Han L; Fan C; Bao L; Ortiz CL; Lin HR; Manocha U; Luo W; Peng Y; Kim WY; Yang LW; Zhang Q
Elife; 2021 Nov; 10():. PubMed ID: 34779768
[TBL] [Abstract][Full Text] [Related]
4. The LINK-A lncRNA activates normoxic HIF1α signalling in triple-negative breast cancer.
Lin A; Li C; Xing Z; Hu Q; Liang K; Han L; Wang C; Hawke DH; Wang S; Zhang Y; Wei Y; Ma G; Park PK; Zhou J; Zhou Y; Hu Z; Zhou Y; Marks JR; Liang H; Hung MC; Lin C; Yang L
Nat Cell Biol; 2016 Feb; 18(2):213-24. PubMed ID: 26751287
[TBL] [Abstract][Full Text] [Related]
5. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
6. LncRNA LUCAT1 facilitates tumorigenesis and metastasis of triple-negative breast cancer through modulating miR-5702.
Mou E; Wang H
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31399501
[TBL] [Abstract][Full Text] [Related]
7. The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.
Garner KEL; Hull NJ; Sims AH; Lamb R; Clarke RB
J Mammary Gland Biol Neoplasia; 2019 Sep; 24(3):245-256. PubMed ID: 31529195
[TBL] [Abstract][Full Text] [Related]
8. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
9. Prolonged oxidative stress down-regulates Early B cell factor 1 with inhibition of its tumor suppressive function against cholangiocarcinoma genesis.
Armartmuntree N; Murata M; Techasen A; Yongvanit P; Loilome W; Namwat N; Pairojkul C; Sakonsinsiri C; Pinlaor S; Thanan R
Redox Biol; 2018 Apr; 14():637-644. PubMed ID: 29169115
[TBL] [Abstract][Full Text] [Related]
10. Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy.
Liu Q; Guan C; Liu C; Li H; Wu J; Sun C
Biomed Pharmacother; 2022 Dec; 156():113861. PubMed ID: 36228375
[TBL] [Abstract][Full Text] [Related]
11. PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes.
Ponente M; Campanini L; Cuttano R; Piunti A; Delledonne GA; Coltella N; Valsecchi R; Villa A; Cavallaro U; Pattini L; Doglioni C; Bernardi R
JCI Insight; 2017 Feb; 2(4):e87380. PubMed ID: 28239645
[TBL] [Abstract][Full Text] [Related]
12. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
[TBL] [Abstract][Full Text] [Related]
13. The circRNA circSEPT9 mediated by E2F1 and EIF4A3 facilitates the carcinogenesis and development of triple-negative breast cancer.
Zheng X; Huang M; Xing L; Yang R; Wang X; Jiang R; Zhang L; Chen J
Mol Cancer; 2020 Apr; 19(1):73. PubMed ID: 32264877
[TBL] [Abstract][Full Text] [Related]
14. MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis.
Chen F; Wang Q; Yu X; Yang N; Wang Y; Zeng Y; Zheng Z; Zhou F; Zhou Y
Cell Death Dis; 2021 Apr; 12(4):370. PubMed ID: 33824311
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA linc00921 suppresses tumorigenesis and epithelial-to-mesenchymal transition of triple-negative breast cancer via targeting miR-9-5p/LZTS2 axis.
Zhang J; Zhang L; Wang J; Zhao J; Zhao X; Zhang C; Han P; Geng C
Hum Cell; 2022 May; 35(3):909-923. PubMed ID: 35179718
[TBL] [Abstract][Full Text] [Related]
16. Elevated expression of the rhythm gene NFIL3 promotes the progression of TNBC by activating NF-κB signaling through suppression of NFKBIA transcription.
Yang W; Li J; Zhang M; Yu H; Zhuang Y; Zhao L; Ren L; Gong J; Bi H; Zeng L; Xue Y; Yang J; Zhao Y; Wang S; Gao S; Fu Z; Li D; Zhang J; Wang T; Shan M; Tang B; Li X
J Exp Clin Cancer Res; 2022 Feb; 41(1):67. PubMed ID: 35180863
[TBL] [Abstract][Full Text] [Related]
17. DOT1L regulates MTDH-mediated angiogenesis in triple-negative breast cancer: intermediacy of NF-κB-HIF1α axis.
Neeli PK; Sahoo S; Karnewar S; Singuru G; Pulipaka S; Annamaneni S; Kotamraju S
FEBS J; 2023 Jan; 290(2):502-520. PubMed ID: 36017623
[TBL] [Abstract][Full Text] [Related]
18. Suppression of breast cancer progression by FBXL16 via oxygen-independent regulation of HIF1α stability.
Kim YJ; Zhao Y; Myung JK; Yi JM; Kim MJ; Lee SJ
Cell Rep; 2021 Nov; 37(8):109996. PubMed ID: 34818544
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
